Striving towards the elimination of HCV infection among PWID

International Journal of Drug Policy, Volume 72,Pages 1-198 (October 2019)

Nearly 200 pages of open access articles from projects and research around the world.

While this special issue highlights some successful efforts towards HCV elimination among people who inject drugs, it also highlights the relative lack of attention to settings in which resources enabling elimination are scarce, and where elimination hopes and potentials are less clear, such as in many low and middle income countries. Strengthening capacity in areas of the world where resources are more limited will be a critical step towards ensuring equity for all so that global HCV elimination among PWID can be achieved.

  • Browse articles here
  • You can also download the full issue as PDF by creating an account and signing in at the above link

Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection

Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. 

PLoS ONE. 2016;11(6):e0150655. doi:10.1371/journal.pone.0150655

Despite effective treatment for recent hepatitis C (HCV) infection, side-effects and adherence concerns limit its use among people who inject drugs (PWID).

This study evaluated health-related quality of life (HRQoL) and social functioning following infection and during recent HCV treatment.

Conclusions:

Social functioning can predict recent HCV treatment uptake and SVR. Efforts to maximise social stability may improve treatment response. Pegylated-interferon treatment is associated with reduced HRQoL on-treatment in an already vulnerable population of PWID that would be better served by interferon-free regimens particularly in treated target at PWID to prevent transmission

  • Access full text (open access) here 

 

Latest research shows Australia on track to cure Hepatitis C

Kirby Institute/UNSW – 21 February 2017

More Australians were treated for their hepatitis C infection in the first year new generation hepatitis C regimens were made available on the Pharmaceutical Benefits Schemes than in the past decade, according to a new report released today by the Kirby Institute at UNSW Sydney.